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Abstract
Background: Horses are much predisposed and susceptible to excessive and acute inflammatory responses that
cause the recruitment and stimulation of polymorphnuclear granulocytes (PMN) together with peripheral blood
mononuclear cells (PBMC) and the release of cytokines. The aim of the study is to develop easy, quick, cheap and
reproducible methods for measuring tumor necrosis factor alpha (TNF-α) and interleukin-1 receptor antagonist
(IL-1Ra) in the equine whole blood cultures ex-vivo time- and concentration-dependently.
Results: Horse whole blood diluted to 10, 20 and 50 % was stimulated with lipopolysaccharide (LPS), PCPwL
(a combination of phytohemagglutinin E, concanavalin A and pokeweed mitogen) or equine recombinant TNF-α
(erTNF-α). TNF-α and IL-1Ra were analyzed in culture supernatants, which were collected at different time points
using specific enzyme-linked immunosorbent assays (ELISA). Both cytokines could be detected optimal in stimulated
20 % whole blood cultures. TNF-α and IL-1Ra releases were time-dependent but the kinetic was different between
them. PCPwL-induced TNF-α and IL-1Ra release was enhanced continuously over 24–48 h, respectively. Similarly,
LPS-stimulated TNF-α was at maximum at time points between 8–12 h and started to decrease thereafter, whereas
IL-1Ra peaked later between 12–24 h and rather continued to accumulate over 48 h. The equine recombinant TNF-α
could induce also the IL-1Ra release.
Conclusions: Our results demonstrate that similar to PCPwL, LPS stimulated TNF-α and IL-1Ra production
time-dependently in whole blood cultures, suggesting the suitability of whole blood cultures to assess the
release of a variety of cytokines in health and diseases of horse.
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Background
Tumor necrosis factor α (TNF-α), in addition to being
cytotoxic for certain tumor cells [1, 2], has turned out to
be a pro-inflammatory cytokine that is involved in the
regulation of immunity and several inflammatory diseases
in humans [3, 4] and animals including horses [5, 6].
These animals are much predisposed and susceptible to
excessive and acute inflammatory responses that cause the
recruitment and stimulation of polymorphnuclear granu-
locytes (PMN) and peripheral blood mononuclear cells
(PBMC) as frequently observed in gastrointestinal diseases
[7], laminitis [8], recurrent airway obstruction [9, 10] and
endometritis [11]. In horses as well as in humans, the sys-
temic release of TNF-α appears to be an essential early
mediator in inflammatory and immunologic reactions dur-
ing host defense [12–14]. Also, several studies have shown
a direct correlation between disease severity/lethality and
TNF-α concentration [7, 15, 16].
Moreover, it has been described that TNF-α can or-
chestrate the production of other cytokines such as
interleukin (IL)-1, IL-6 and IL-8 to promote inflammation
including increased leukocyte extravasation [17, 18],
cellular and tissue damage in multiple organs and clin-
ical features of sepsis [19, 20], both in experimental
animal disease models and in human diseases. Evidence
exists that excessive production of the cytokines TNF-α
and IL-1 significantly contributes to the development
of multiple organ damage in endotoxemia and sepsis in
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humans [21], in the equine endometritis [22], equine
asthma [5, 23] and colic [7].
The elevated TNF-α and IL-1 levels trigger often high
production of the interleukin-1 receptor antagonist (IL-
1Ra), the first described naturally occurring cytokine or
hormone-like molecule that functions as a specific IL-1
receptor antagonist and produced by various cell types,
including mononuclear cells and neutrophils [24, 25].
IL-1Ra is elevated in plasma of human patients with a
variety of inflammatory, infectious, and post-surgical
conditions, indicating the importance of hepatic production
of this anti-inflammatory protein (for review see reference
[26]). Also, administered LPS increased the plasma concen-
tration of IL-1 and concomitantly of IL-1Ra [27], suggesting
highly likely that IL-1Ra diffuses from the circulation into
tissues and influences the local ratio of IL-1Ra to IL-1 to
suppress competitively the IL-1, subsequently to attenuate
IL-1-induced TNF-α and IL-6 production [25, 28]. In vitro,
it has been also shown that TNF is capable of inducing the
production of IL-1Ra [29, 30]. TNF-α has been described
to be associated with the human endotoxemia and several
inflammatory disorders, and blocking of this cytokine
seems to inhibit endotoxin-induced IL-1Ra release [21];
indeed, this relationship to TNF-α has not been examined
in horses.
Generally, in the horse, cytokine production can be in-
fluenced by several factors including various nutritional,
physiological and pathological factors as well as drugs;
thus, there is still much interest in measuring the con-
centrations of different cytokines. In man, successful ex-
vivo ELISA-based method of TNF-α measurement has
been well established in whole blood system [17, 31]
which is quick, less expensive than the analysis in iso-
lated cell systems and can be adapted to field use. In
contrast, in horses, current literature review indicates
that different matrices have been used to assess TNF-α
production ex vivo which did not warrant the generation
of uniform data; for example, in bronchoalveolar lavage
fluid (BALF) [32], serum [15], plasma [33] or isolated
and cultured leukocytes [34–36]. Indeed, different proto-
cols showed culturing PMN influences cell functions
and presumably cytokine release [37]. Despite the fact
that there are also some studies that used equine whole
blood to assess cytokine releases, little was attempted to
assess systematically the kinetics of TNF-α production
in relation to IL-1Ra production and in different volumes
of the whole blood as specialized circulating connective
tissue by retaining all blood components.
Thus, we have used the equine whole blood cultures
to investigate: first, the relationship between cultures of
equine whole blood dilutions and stimulated TNF-α and
IL-1Ra release; second, to characterize time-concentration-
responses of TNF-α and IL-1Ra production within indi-
viduals and different blood dilutions; third, effects of
lipopolysaccharide (LPS), a combination of phytohem-
agglutinin E, concanavalin A and pokeweed mitogen
(PCPwL) and equine recombinant TNF-α (erTNF-α) on
TNF-α and IL-1Ra in whole blood cultures. Finally, we
wished to evaluate, to our knowledge the first time,
whether elevated TNF-α can enhance the IL-Ra activity
in the equine whole blood cultures. Our results indicate
that TNF is involved not only in the secretion of agon-
istic members of the cytokine network in endotoxemia
but also in that of an important antagonistic member
(i.e., IL-1Ra), assuming that blockade of TNF-α results
in a general down-regulation of the cytokine system.
Methods
Animals
For the kinetic time-course studies of TNF-α and IL-1Ra
releases, blood samples were collected from three-five
healthy horses of mixed breeds and 8–14 years of age. They
were neither under treatment for the last three weeks be-
fore sampling nor were given immune-suppressing drugs.
Animals were kept in an individual pen, fed with hey and
concentrates three times a day, but had access to water ad
libitum. Blood samples were collected from horses, which
belong to the Large Animal Clinic of the Leipzig University.
Reagent and antibody dilutions
TNF-α antibodies1 were reconstituted to final stock
concentrations of 1 mg/ml (capture) and 0.25 mg/ml
(detection) in ultra-pure water.2 Complete RPMI 1640
medium contained basal RPMI 1640 medium2, Penicillin
G2 (100 U/ml), Streptomycin2 (100 μg/ml) and heparin2
(10 U/ml). The TNF-α-capture antibody was diluted in
0.1 M NaHCO3 solution with ultra-pure water to a work-
ing concentration of 3 μg/ml. The detection antibody was
diluted to a working concentration of 250 ng/ml in PBST-
buffer, containing 2 % heat inactivated (56 °C, 30 min) and
sterile-filtered rabbit serum.3 Streptavidin-horseradish-
peroxidase4 (HRP) was diluted 1:50000 in PBST contain-
ing Dulbecco’s phosphate buffered saline (PBS) solution5
and 0.1 % Tween 20.6 With regard to IL-1Ra, antibodies
and reagents were processed in accordance with the man-
ufacturer’s instructions (Equine IL-1ra/IL-1 F3 DuoSet
ELISA).7
Blood sampling, whole blood cell culture and stimulation
Blood samples were collected via jugular venipuncture
into 9 mL vacutainer tubes with Li-Heparin (16 U ×mL−1)
(S-Monovette).8 Blood dilutions, culturing and whole blood
stimulations were carried out under sterile conditions.
Within 30 min after sampling, whole blood was diluted at a
ratio of 1:2 (50 %), 1:5 (20 %) and 1:10 (10 %) in a complete
RPMI 1640 medium, respectively.
For the stimulation of TNF-α and IL-1Ra releases, di-
luted blood was incubated in 24-well culture plates (total
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volume 2 ml/well). Samples were stimulated with either
LPS9 (1000 ng/ml; Escherichia coli O111:B4) or with
PCPwL (100 ng/ml) (a combination of phytohemagglu-
tinin E,10 concanavalin A10 and pokeweed mitogen10) (as
positive control) or with medium alone. Moreover,
whole blood cultures were treated with the equine re-
combinant TNF-α11 (erTNF-α; 20 ng/ml) to stimulate
IL-1Ra antagonist release. Each culture plate was then
incubated for 72 h at 37 °C under 5 % CO2 atmosphere.
To assess the time course of cytokine releases, aliquots
of the supernatant/well were collected at time points of
0, 1, 2, 4, 6, 8, 12, 16, 24, 48 and 72 h. These aliquots
were centrifuged (10000 rpm) at 4 °C for 3 min and the
supernatant was separated from the cell debris and
frozen at −20 °C until analysis of the cell-associated
cytokines.
Detection of TNF-α and IL-1Ra production
Concentrations of cytokines in whole blood cell culture
supernatants were determined by enzyme-linked immuno-
sorbent assay (ELISA) system. All samples from each blood
dilutions were analyzed in one ELISA.
Measurement of TNF-α
The TNF-α protein level was measured using the equine
TNF-α sandwich ELISA that was established in our la-
boratory. For this purpose, 96-microtiter well plates12
were coated with 100 μl/well of a polyclonal antibody
specific for equine TNF-α and incubated overnight at 4–
6 °C. Thereafter, samples were allowed to reach room
temperature. Plates were then washed twice with 400 μl/
well washing buffer (distilled water containing 0.9 % NaCl
and 0.05 % Tween 20) using an automated 8-channel
washer.13
Assay conditions were optimized by adding a series of
calibrators on every assay plate that consisted of 7-point
serial dilutions of equine recombinant TNF-α starting
from 24.3 ng/ml to 0.033 ng/ml in duplicates in complete
RPMI 1640 cell culture medium containing PBST in the
presence of 10, 20 or 50 % horse serum. Also, duplicate
wells of each plate contained only medium. For each ELISA
plate, the optical density (OD) at 450 nm was measured,
and the standard curves were established by plotting mean
absorbance for each standard concentration against the tar-
get protein concentration with OD 450 nm as the Y-axis
using GraphPad Prism Software program. These curves
were used to determine protein expression levels.
Basal and stimulated levels of TNF-α and IL-1Ra in
whole blood culture supernatant samples were measured
using ELISA. In brief, for each point of assay, 50 μl of
pure cell culture supernatant were pipetted into each
well of 96-microtiter well plates and diluted 1:2 by add-
ing 50 μl PBST-buffer. Samples were then incubated for
1 h at room temperature. After three times rinsing the
plates with washing buffer, 100 μl of the polyclonal
biotin-labeled detecting antibody were added to each
sample and incubated for further 2 h at room
temperature. After three washing steps, plates were in-
cubated with 100 μl horseradish peroxidase-conjugated
streptavidin for 1 h at room temperature. After four
washing steps, 100 μl of freshly prepared substrate so-
lution (containing 3 mM H202 and 1 mM tetramethyl-
benzidine14 (TMB) in 0.2 M citrate buffer, pH 4.0) were
added to each well. The chromogenic substrate was
converted from colorless to blue by streptavidin-HRP
conjugate. The reaction was stopped after 15 min at
room temperature by adding 50 μl of 1 M sulfuric acid
solution, and the optical density (OD) was read at 450
and 620 nm with a spectrophotometer (Tecan Plate
reader15). The levels of TNF-α in whole blood supernatant
samples were interpolated from the erTNF-α standard
calibration curves calculated as described above.
Measurement of IL-1Ra
IL-1Ra concentrations were measured in whole blood
culture supernatants according to the manufacturers’
guidelines with slight modifications. Briefly, 96-microtiter
well plates were coated with polyclonal equine anti-IL-1Ra
antibody and incubated overnight at room temperature,
followed by washing and blocking steps. Freshly thawed
whole blood supernatant samples and the equine IL-1Ra
standard (at different concentrations starting from 40 ng/
ml to 0.16 ng/ml) were diluted at a ratio of 1:10 and in-
cubated. Following several washing steps, biotinylated
secondary IL-1Ra antibody, streptavidin-HRP conjugate
and enzyme substrate were added at different time points
as given in the guidelines. Further procedures were per-
formed analogous to the TNF-α ELISA.
Data calculation and statistical analysis
Results are presented as means ± SEM. The levels of
TNF-α and IL-1Ra in whole blood supernatants were
interpolated from the erTNF-α and IL-1Ra standard
calibration curves which were established using Graph-
Pad Prism 6.0116. Variations in cytokine productions in
the different whole blood cultures and time courses of
incubation as well as different cytokine stimulants were
assessed by two-way analysis of variance (ANOVA) using
SigmaPlot 12.517 with Holm-Sidak post-hoc test. Cytokine
productions in different culture conditions were plotted
and statistical significance was calculated. Differences
giving P value < 0.05 were considered significant.
Results
Relationship between whole blood dilutions and cytokine
releases
The ex vivo production of TNF-α and IL-1Ra was deter-
mined in horses using heparin-displaced whole blood
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samples collected in a single draw. Samples were diluted
1:2 (50 %), 1:5 (20 %) and 1:10 (10 %) with complete
RPMI 1640 medium. The PCPwL- but also LPS-stimulated
TNF-α and IL-1Ra production was linear with different
concentrations of the equine whole blood, whereby the
highest cytokine concentration was achieved at whole blood
dilution of 50 %. In all whole blood dilutions, PCPwL
stimulated continuously TNF-α release over 24 h to the
maximum and similarly but within 12 h of stimulation,
LPS activated TNF-α production (Table 1). The stimulation
with these both stimulating agents and additionally with
erTNF-α yielded on average a maximum IL-1Ra produc-
tion in all whole blood dilutions over 48 h of stimulation
(Table 2). Despite the linearity of ELISA signals for TNF-α
and IL-1Ra as a function of whole blood dilution, there
were high background signals and strong adherence of di-
luted blood in the pipette tips at a volume of 50 % (with
large variation in cytokine concentration). These errors
were considered significant; thus, in all subsequent experi-
ments, 20 % equine whole blood dilution, which provided
low data variation of cytokine concentration, was routinely
used, since also 10 % dilution tended not to result in
reliable data.
Time-course kinetics of TNF-α release in whole blood cell
culture
In the next step, the relationship between equine whole
blood dilutions and time-course of LPS-stimulated TNF-
α production in comparison to PCPwL was examined.
As depicted in Figs. 1 and 2, the mean production of
TNF-α in relation to whole blood dilution was affected
by time. One hour after LPS addition, the level of TNF-
α started to increase and maximum levels were achieved
at the incubation time between 8–12 h. Thereafter,
TNF-α concentration started to decrease continuously
up to 72 h (Fig. 1a). In whole blood cultures of both 10
and 20 % dilutions, PCPwL stimulated the TNF-α pro-
duction to a similar extent as LPS, but the concentration
of TNF-α increased gradually and peaked until up to
72 h while in 50 % diluted whole blood cultures TNF-α
level declined continuously after 24 h of incubation
(Fig. 1b). Comparing both stimulating agents, LPS seems
to stimulate TNF-α production more than PCPwL, and
this was also dependent on whole blood dilutions (Fig. 2).
Together, due to the data fluctuation of TNF-α releases,
which were obtained at whole blood dilutions of 10 or
50 % and the variable peak time courses obtained after
PCPwL and also after LPS stimulation, 12-h incubation
is assumed to be an optimal condition to measure TNF-α
in 20 % whole blood cultures.
Time-course kinetics of IL-1Ra activation
Strong and significant activation of IL-1Ra release was
obtained in 50 % diluted equine whole blood cultures re-
gardless of the used stimulating agents (LPS, PCPwL or
erTNF-α) (Fig. 3a-c). Interestingly, it was able to detect
IL-1Ra release first after about 4 h of stimulation of the
whole blood cultures of 20 and 50 % dilutions and the
maximum response was obtained after 48 h and declined
after 72 h. Similar data of IL-1Ra release were obtained
when 10 % whole blood cultures were stimulated but
maximum response was obtained here after about 72 h
of incubation. As shown in Fig. 4, there were little sig-
nificant differences between IL-1Ra levels obtained from
three whole blood dilutions stimulated by all three
stimulating agents (LPS, PCPwL or erTNF-α) over 72 h.
Discussion
The present study dissects equine whole blood dilution-
dependent and time-course secretion of TNF-α and IL-
1Ra after stimulation by PCPwL, LPS as well as erTNF-α
(only IL-1Ra was stimulated) ex vivo. The decisive re-
sults were: PCPwL and also LPS triggered TNF-α and
IL-1Ra releases in a blood volume-dependent manner
(50 % > 20 % >10 %). In whole blood cultures, TNF-α ex-
hibited a kinetic profile similar to that of IL-1Ra, but
peaked explicitly prior to IL-1Ra activity. TNF-α peaked
8–12 h after LPS addition while the IL-1Ra level was at
Table 1 Maximal TNF-α concentration after stimulation with
LPS or PCPwL
BC (%) LPS PCPwL
8 h 24 h 72 h
10 % 296 ± 153 103 ± 103 345 ± 106
20 % 538 ± 219 304 ± 164 517 ± 163
50 % 1104 ± 279 865 ± 187 661 ± 316
Supernatant TNF-α level (pg/ml) was compared between different whole blood
volumes after stimulation with LPS or PCPwL. Maximal concentrations were
obtained after the start of stimulation at various time points until 72 h. Data
represent means ± SEM of three different horses. BC, blood concentration
Table 2 Maximal IL-1Ra production after stimulation with LPS, PCPwL or erTNF- α
BC (%) LPS PCPwL erTNF-α
48 h 72 h 48 h 48 h 72 h
10 % 5643 ± 1520 5809 ± 1426 8045 ± 2965 5083 ± 2364 5120 ± 2323
20 % 11368 ± 1713 8502 ± 1667 11451 ± 1620 11167 ± 994 8829 ± 178
50 % 26375 ± 4842 21260 ± 7332 25982 >40000 27529 ± 4010
Supernatant IL-1Ra production (pg/ml) was compared between different whole blood volumes after stimulation with LPS, PCPwL or erTNF-α. Maximal concentrations
were obtained after the start of stimulation at various time points until 72 h. Data represent means ± SEM of three different horses. BC, blood concentration
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maximum 24 h later and remained at that level for further
24 h. The effect of several stimuli on cytokine releases was
often investigated in isolated leukocytes of horses [34–36]
and humans [38, 39]. Also, cytokines could be assessed in
human whole blood cultures [31, 37–39], but to our
knowledge, very rarely or even not analyzed the time-
dependent kinetics of TNF-α release in relation to IL-1Ra
production in an equine whole blood-volume-dependent
manner.
For reasons that the optimal stimulation conditions to
assess cytokine releases in the equine whole blood cul-
tures were not well known, the aim of the current study
was to first find out which blood volumes can provide a
reproducible signal-to-noise ratio of cytokine standard
and sample concentration curves. In the whole blood
medium, which resembles closely the physiological mi-
lieu, it was observed that the PCPwL- or LPS-stimulated
TNF-α and IL-1Ra release was reduced in whole blood
cultures with increasing dilutions (cf. Tables 1 and 2).
Indeed, the data obtained from whole blood cultures of
1:2-diltution (50 %-vol.) were subjected fluctuations, pre-
sumably due to more background signals as a result of
strong adherence of the blood to the pipette tips when
compared to the data obtained from equine whole blood
cultures of the 20 and 10 % dilutions. Even if 10 % whole
blood samples would require smaller starting blood sam-
ples to assess cytokines, signals obtained here were
weak. On the other hand, the 1:5-dilution (20 %-vol.) of
the whole blood delivered consistently high reproducible
cytokine data. This validated novel, cheap, optimized
and straightforward approach was further used to quan-
tify TNF-α and IL-1Ra in whole blood cultures of the
horse, and can be suggested for the use in field condi-
tions. Our data are in agreement with data from earlier
studies that demonstrated stable cytokine production in
diluted human whole blood cultures (dilution ranged:
1:4 to 1:10) [31, 38, 39]. These authors compared whole
blood cultures with isolated monocytes or PBMC and
showed constant cytokine reproducibility in whole blood
cultures than in isolated cells, thus, suggested that whole
Fig. 1 Effect of time and blood dilution on TNF-α production in whole blood culture. Time-dependent TNF-α production was measured in equine
whole blood cell culture supernatants obtained from different blood volume dilutions after stimulation by LPS (1000 ng/ml) (a) and PCPwL
(100 ng/ml) (b). 10 % (■), 20 % (▲), and 50 % (▼) whole blood volumes were used to assess TNF-α over 72 h (hr). Data represent means ± SEM
of three different horses. ** p < 0.001/* p < 0.05/(*) 0.05≥ p < 0.1 versus 10 % BC, ##p < 0.001/#p < 0.05/(#) 0.05 ≥ p < 0.1 versus 20 % BC. BC,
blood concentration
Fig. 2 Comparison of LPS- and PCPwL-stimulated TNF-α production. LPS- and PCPwL-stimulated TNF-α production was measured in 10 % (a),
20 % (b) and 50 % (c) whole blood cultures over time. Data represent means ± SEM of three different horses. ** p < 0.001/* p < 0.05/(*) 0.05≥ p < 0.1.
BC, blood concentration
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blood is a better suited medium than isolated blood
cell cultures for cytokine studies in humans. Even
though in the current study leukocytes were not iso-
lated, it can be suggested that large-scale ex vivo
cytokine assessment can be undertaken with equine
whole blood cultures.
Similar to the effect of whole blood dilution on equine
TNF-α and IL-1Ra production, there was an effect of
time on the release of both cytokines ex vivo after
stimulation with PCPwL or LPS. With regard to TNF-α,
the release kinetics in whole blood stimulation ex vivo
were similar to those reported in vivo after LPS-challenge
of horses [40–42]. In these in vivo models of endotoxemia,
the low-dose LPS challenge of horses resulted in a
predictable effect on increasing plasma TNF-α activity
that peaked between 1–4 h (average 1.5–2.5 h). In
our study, cytokine levels increased after 1-h stimula-
tion of the equine whole blood cultures with LPS and
peaked between 8–12 h. This time was considered as
an optimal incubation condition for further experi-
ments, since stimulation of blood cultures for longer
times resulted in decreased TNF-α production e.g.
until 72 h.
Interestingly, we could also demonstrate the first time
that IL-1Ra can be detected in relation to TNF-α pro-
duction in the equine whole blood cultures and can be
also affected with time. Both PCPwL and LPS could in-
duce a continuous production of IL-1Ra over 48 h, indi-
cating that the elevated TNF-α may contribute to the
high level of IL-1Ra even beyond the peak time points,
which were observed for the former cytokine. The activated
IL-1Ra levels were much higher than the levels of TNF-α,
presumably, to block the biological effects of IL-1 [25, 27]
which is concomitantly released during inflammatory
processes in several tissue and organ systems. Further-
more, in the current study, stimulation of the equine
whole blood cultures with the equine recombinant
TNF-α (erTNF-α) resulted in enhanced activity of IL-
1Ra, in agreement with the data obtained from human
studies [43–45]. In man, this relationship has been
shown during endotoxemia [21] and high level of
acute-phase protein [46, 47] and could be linked to the
involvement of TNF-α in the course of several diseases.
However, in horses, excessive IL-1Ra production in rela-
tion to TNF-α release has not yet been associated with
disease pathogenesis and severity. In the first place, IL-1Ra
Fig. 3 Effect of Time and dilution on IL-1Ra production in whole blood culture. IL-1Ra production was measured in equine whole blood cell culture
supernatants obtained from different blood volume dilutions (10 % (■), 20 % (▲), and 50 % (▼)) stimulated by LPS (1000 ng/ml) (a) PCPwL
(100 ng/ml) (b) and erTNF-α (20 ng/ml) (c) over 72 h. Data represent means ± SEM of three different horses. over 72 h (hr). ** p < 0.001/
*p < 0.05/(*) 0.05 ≥ p < 0.1 versus to 10 % BC, ##p < 0.001/#p < 0.05/(#) 0.05 ≥ p < 0.1versus to 20 % BC; BC, blood concentration
Fig. 4 Comparison of LPS-, PCPwL- and erTNF-α-stimulated IL-1Ra production. LPS-, PCPwL- and erTNF-α-stimulated IL-1Ra production
was measured in 10 % (a), 20 % (b) and 50 % (c) whole blood cultures over time. Data represent means ± SEM of three different horses.
**p < 0.001/*p < 0.05/(*) 0.05 ≥ p < 0.1. BC, blood concentration
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is claimed to attenuate the IL-1-dependent activities [25]
which are necessary in tissue remodeling which often
occur in several fibrotic equine diseases such as in the re-
current airway obstruction (RAO).
Conclusions
Together, this study indicates the suitability of whole
blood cultures to assess ex vivo or in vivo the production
of a variety of cytokines of healthy or diseased horses
(e.g. inflammatory disorders of the airways, gastro-
intestinal tract, uterus, liver etc.), presumably, more
than isolated PMN or PBMC cultures. The equine
whole blood assay system is additionally an efficient tool
to elucidate interactions of cytokines within the inflamma-
tory responses and may provide equine veterinarians with
new therapeutic approaches. Dilution of the whole blood
to a ratio of 1:5 (20 %) and an incubation time of 12 h can
be considered as optimal conditions to assess stimulated
cytokines.
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